José Guerreiro , Sónia Romano , Inês Teixeira , Klára Dimitrovová , Rúben Pereira , António Teixeira Rodrigues , Ema Paulino
{"title":"The impact of community pharmacies on equity in access to professional rapid antigen testing for SARS-CoV-2 in Portugal","authors":"José Guerreiro , Sónia Romano , Inês Teixeira , Klára Dimitrovová , Rúben Pereira , António Teixeira Rodrigues , Ema Paulino","doi":"10.1016/j.ejps.2025.107019","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Amid the COVID-19 pandemic, various public health measures were adopted to reduce the transmission risk, including the full reimbursement of SARS-CoV-2 professional rapid antigen detection tests (Ag-RDT) conducted in clinical pathology laboratories, community pharmacies (CPs), and other authorized entities. This study aimed to assess the impact of integrating CPs into the Portuguese National Health Service (NHS) testing strategy on the capacity of professional Ag-RDT delivery, and to compare the equity in testing access with and without CPs participation.</div></div><div><h3>Methods</h3><div>This analytical cross-sectional study assessed the impact of adding CPs into the testing strategy based on two main outcomes by municipality: (i) average distance (in Kilometres) of the population to the nearest Ag-RDT site; and (ii) the average number of weekly hours available to testing per 1,000 inhabitants, as of January 31, 2022. Two scenarios were considered: with and without CPs. Access inequalities were evaluated using Lorenz curves and Gini coefficients. A subgroup inequality analysis was conducted based on three socio-demographic indicators: population density, aging index, and per capita purchasing power index.</div></div><div><h3>Results</h3><div>A total of 1,369 (65.1 %) pharmacies and 735 (34.9 %) laboratories and other entities provided free Ag-RDT to the population. The average distance to the nearest Ag-RDT location was 3.7 km, which decreased to 1.8 km with the inclusion of CPs. Overall, there were 11.5 weekly hours per 1,000 inhabitants available for testing with CPs, compared to 2.1 h without CPs (<em>p</em> < 0.0001). The Gini coefficient for distance distribution decreased from 0.50 to 0.42 with CPs inclusion (-16.8 %). For the distribution of weekly hours, the Gini coefficient decreased from 0.42 to 0.26 (-38.6 %). The reduction was higher in municipalities with lower population density (-43.3 %), higher aging index (-51.3 %), and lower per capita purchasing power index (-54.6 %).</div></div><div><h3>Conclusions</h3><div>Pharmacies play a crucial role in mitigating geographical and socioeconomic inequalities in healthcare access. Without CPs, the provision of Ag-RDT services would result in significant territorial gaps, exacerbating disparities among already vulnerable population groups.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"206 ","pages":"Article 107019"},"PeriodicalIF":4.3000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725000181","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Amid the COVID-19 pandemic, various public health measures were adopted to reduce the transmission risk, including the full reimbursement of SARS-CoV-2 professional rapid antigen detection tests (Ag-RDT) conducted in clinical pathology laboratories, community pharmacies (CPs), and other authorized entities. This study aimed to assess the impact of integrating CPs into the Portuguese National Health Service (NHS) testing strategy on the capacity of professional Ag-RDT delivery, and to compare the equity in testing access with and without CPs participation.
Methods
This analytical cross-sectional study assessed the impact of adding CPs into the testing strategy based on two main outcomes by municipality: (i) average distance (in Kilometres) of the population to the nearest Ag-RDT site; and (ii) the average number of weekly hours available to testing per 1,000 inhabitants, as of January 31, 2022. Two scenarios were considered: with and without CPs. Access inequalities were evaluated using Lorenz curves and Gini coefficients. A subgroup inequality analysis was conducted based on three socio-demographic indicators: population density, aging index, and per capita purchasing power index.
Results
A total of 1,369 (65.1 %) pharmacies and 735 (34.9 %) laboratories and other entities provided free Ag-RDT to the population. The average distance to the nearest Ag-RDT location was 3.7 km, which decreased to 1.8 km with the inclusion of CPs. Overall, there were 11.5 weekly hours per 1,000 inhabitants available for testing with CPs, compared to 2.1 h without CPs (p < 0.0001). The Gini coefficient for distance distribution decreased from 0.50 to 0.42 with CPs inclusion (-16.8 %). For the distribution of weekly hours, the Gini coefficient decreased from 0.42 to 0.26 (-38.6 %). The reduction was higher in municipalities with lower population density (-43.3 %), higher aging index (-51.3 %), and lower per capita purchasing power index (-54.6 %).
Conclusions
Pharmacies play a crucial role in mitigating geographical and socioeconomic inequalities in healthcare access. Without CPs, the provision of Ag-RDT services would result in significant territorial gaps, exacerbating disparities among already vulnerable population groups.
期刊介绍:
The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development.
More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making.
Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.